A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma

Abstract Background BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary resistance and relapse exist with single-target immunotherapy. Bispecific CARs are proposed to mitigate these limitation...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Heng Mei, Chenggong Li, Huiwen Jiang, Xinying Zhao, Zhiping Huang, Dan Jin, Tao Guo, Haiming Kou, Lin Liu, Lu Tang, Ping Yin, Zhihui Wang, Lisha Ai, Sha Ke, Yimeng Xia, Jun Deng, Lei Chen, Li Cai, Chunyan Sun, Linghui Xia, Gaoquan Hua, Yu Hu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2021-10-01
coleção:	Journal of Hematology & Oncology
Assuntos:	Chimeric antigen receptor-T cells Multiple myeloma BCMA CD38 Bispecific CAR
Acesso em linha:	https://doi.org/10.1186/s13045-021-01170-7
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!